Literature DB >> 9109644

Chromium oligopeptide activates insulin receptor tyrosine kinase activity.

C M Davis1, J B Vincent.   

Abstract

A possible new mechanism for the amplification of insulin receptor tyrosine kinase activity in response to insulin has been identified. The chromium-containing oligopeptide low molecular weight chromium-binding substance (LMWCr) does not effect the tyrosine protein kinase activity of rat adipocytic membrane fragments in the absence of insulin; however, insulin-stimulated kinase activity in the membrane fragments is increased up to 8-fold by the oligopeptide. Using isolated rat insulin receptor, LMWCr has been shown to bind to insulin-activated insulin receptor with a dissociation constant of circa 250 pM, resulting in the increase of its tyrosine protein kinase activity. The ability of LMWCr to stimulate insulin receptor tyrosine kinase activity is dependent on its chromium content. The results appear to explain the previously poorly understood relationship between chromium and adult-onset diabetes and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109644     DOI: 10.1021/bi963154t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  35 in total

1.  The use of chromium(III) to supercharge peptides by protonation at low basicity sites.

Authors:  Changgeng Feng; Juliette J Commodore; Carolyn J Cassady
Journal:  J Am Soc Mass Spectrom       Date:  2014-11-14       Impact factor: 3.109

2.  Dietary chromium supplementation for targeted treatment of diabetes patients with comorbid depression and binge eating.

Authors:  Kimberly A Brownley; Charlotte A Boettiger; Laura Young; William T Cefalu
Journal:  Med Hypotheses       Date:  2015-03-27       Impact factor: 1.538

3.  Isolation and characterization of low-molecular-weight chromium-binding substance (LMWCr) from chicken liver.

Authors:  Margarita Viera; C Michele Davis-McGibony
Journal:  Protein J       Date:  2008-09       Impact factor: 2.371

Review 4.  Molecular mechanisms of chromium in alleviating insulin resistance.

Authors:  Yinan Hua; Suzanne Clark; Jun Ren; Nair Sreejayan
Journal:  J Nutr Biochem       Date:  2012-04       Impact factor: 6.048

5.  Cr-enriched yeast: beyond fibers for the management of postprandial glycemic response to bread.

Authors:  Amalia E Yanni; Nikoleta Stamataki; Maria Stoupaki; Panagiotis Konstantopoulos; Irene Pateras; Nikolaos Tentolouris; Despoina Perrea; Vaios T Karathanos
Journal:  Eur J Nutr       Date:  2016-02-25       Impact factor: 5.614

6.  Chromium Therapy for Insulin Resistance Associated with HIV-Disease.

Authors:  Seth A Stein; Margaret Mc Nurlan; Brett T Phillips; Catherine Messina; Dennis Mynarcik; Marie Gelato
Journal:  J AIDS Clin Res       Date:  2013-09-07

Review 7.  Current concepts about chromium supplementation in type 2 diabetes and insulin resistance.

Authors:  Zhong Q Wang; William T Cefalu
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810

8.  Crystalline and water soluble Cr(4+) and Cr(5+) model compounds for chromium toxicity studies.

Authors:  Chris M Ramsey; Naresh S Dalal
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

9.  Chromium supplementation improves glucose tolerance in diabetic Goto-Kakizaki rats.

Authors:  Aicha Abdourahman; John G Edwards
Journal:  IUBMB Life       Date:  2008-08       Impact factor: 3.885

Review 10.  Chromium does not belong in the diabetes treatment arsenal: Current evidence and future perspectives.

Authors:  Gijs Wd Landman; Henk Jg Bilo; Sebastiaan T Houweling; Nanne Kleefstra
Journal:  World J Diabetes       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.